Insurance Benefit Design: How Plans Use Generics to Cut Costs

Imagine you have a prescription for a common medication. You walk into the pharmacy, and the cashier tells you the brand-name version costs $120, but the generic is just $4. Most of us would grab the generic without thinking twice. But what if that $4 price tag wasn't actually saving you money? What if the insurance company was pocketing the difference while making it look like they were helping your wallet?

This is the hidden reality behind insurance benefit design. Health plans don't just randomly decide which drugs are cheap and which are expensive. They engineer complex systems to steer you toward generic medications. The goal is simple: cut costs. But the methods involve tiered formularies, opaque pricing models, and Pharmacy Benefit Managers (PBMs) that act as gatekeepers between you and your medicine.

The Engine Behind Your Prescription Bill

To understand why generics are so central to your insurance plan, we first need to look at who actually handles your prescriptions. It’s rarely your health insurance company directly. Instead, they outsource this job to Pharmacy Benefit Managers, or PBMs.

PBMs are the middlemen that negotiate drug prices with manufacturers and pharmacies. In 2023, three major PBMs-CVS Caremark, OptumRx, and Express Scripts-processed 83% of all prescription transactions in the United States. Their primary tool for cost control is the formulary. A formulary is essentially a list of approved drugs, organized into tiers based on cost.

Here is how the typical tier system works:

• Tier 1: Preferred generic drugs. These usually have the lowest copay, often ranging from $0 to $10.
• Tier 2: Non-preferred generics or preferred brand-name drugs. Copays here might jump to $25-$50.
• Tier 3: Non-preferred brand-name drugs. These can cost $60-$100 or more per prescription.
• Tier 4: Specialty drugs. These often use coinsurance, where you pay a percentage of the total cost.

By placing generics in Tier 1, insurers create a massive financial incentive for you to choose them. According to data from the Kaiser Family Foundation, this structure has been highly effective. In 2022, PBMs processed 6.8 billion generic prescription claims, representing 91.5% of all prescriptions dispensed. Despite this huge volume, generic drugs accounted for only 22% of total drug spending. That is a significant efficiency gain for the system.

How Much Do Generics Actually Save?

The argument for generic-first benefit design is rooted in substantial savings. Generic drugs typically cost 80-85% less than their brand-name counterparts because manufacturers don’t have to repeat expensive clinical trials; they only need to prove bioequivalence to the FDA.

The scale of these savings is enormous. An analysis by the IQVIA Institute for Human Data Science found that generic drugs saved the U.S. healthcare system approximately $3.7 trillion over the decade from 2013 to 2022. That breaks down to annual savings exceeding $370 billion. For employers and government programs like Medicare and Medicaid, these numbers justify the aggressive push for generic utilization.

However, "system savings" does not always equal "patient savings." This is where the benefit design gets complicated. While the insurer saves billions, patients often wonder if they are seeing the full benefit of those lower wholesale prices.

The Hidden Costs: Spread Pricing and Clawbacks

If generics are so cheap, why do some patients still feel like they are paying too much? The answer lies in spread pricing and copay clawbacks.

Spread pricing occurs when a PBM charges an employer or health plan more for a drug than what the pharmacy actually paid for it. The PBM keeps the difference as profit. A study from the USC Schaeffer Center found that patients could be overpaying by $10-$15 per prescription due to these opaque practices. Even though the generic drug itself is cheap, the markup added by intermediaries can inflate the final cost.

Copay clawbacks happen when a patient pays a fixed copay (say, $10), but the actual cost of the drug to the insurer is lower (say, $5). In many contracts, the insurer is allowed to keep that extra $5 rather than passing it back to the patient. This means the low copay you see isn't always reflecting the true market value of the drug.

These practices have drawn criticism. Dr. Erin Trish from the USC Schaeffer Center testified before Congress in June 2023, stating that "the current system funnels savings from low-cost generics into intermediaries' pockets rather than patients." This tension between systemic cost containment and individual affordability is the core conflict in modern insurance benefit design.

Steering Behavior: Step Therapy and Prior Authorization

Lowering copays is just one part of the strategy. Insurers also use administrative hurdles to force generic usage. Two of the most common tools are step therapy and prior authorization.

Step therapy requires patients to try a lower-cost generic drug first before the insurance will cover a more expensive brand-name alternative. If the generic doesn't work, the patient must go through an appeal process to get coverage for the brand name. As of 2023, 92% of Medicare Part D plans used step therapy protocols.

Prior authorization requires doctors to submit additional paperwork proving medical necessity before a specific drug is covered. This creates friction. A survey found that 22% of Medicare beneficiaries experienced issues obtaining prior authorization for brand-name drugs when generics were available, with 14% reporting that their doctor had to submit multiple appeals.

While these measures effectively reduce brand-name utilization, they can lead to frustration. Some physicians report that patients experience adverse effects after being switched to generics through mandatory substitution programs. A Medscape poll in 2023 found that 31% of physicians reported such cases. The benefit design prioritizes cost efficiency, sometimes at the expense of convenience or perceived continuity of care.

Different Programs, Different Rules

Not all insurance plans handle generics the same way. The approach varies significantly depending on whether you are covered by commercial insurance, Medicare, or Medicaid.

Commercial Insurance: Many employers now use High-Deductible Health Plans (HDHPs) paired with Health Savings Accounts (HSAs). In these plans, generic copays are often lower even before the deductible is met. Self-insured employers have been particularly aggressive, with studies showing savings of 9-15% by substituting therapeutically equivalent lower-cost options.

Medicare Part D: Medicare covers over 50 million beneficiaries. Its benefit design includes a standardized formulary structure. In 2025, the Inflation Reduction Act implemented an out-of-pocket cap of $2,000 for seniors, fundamentally changing the incentive structure. Seniors no longer face catastrophic drug costs, which may slightly reduce the pressure to choose generics solely for survival-level affordability, though generics remain the cheapest option.

Medicaid: Medicaid programs operate under federal Upper Payment Limits (UPL), capping reimbursement for generics at 250% of the average manufacturer price. Medicaid achieves high generic dispensing rates (89.3% in 2022), resulting in estimated annual savings of $1.2 billion. Looking ahead, the CMS GENEROUS Model is set to launch in 2026, aiming to negotiate lower prices directly with manufacturers, potentially reducing Medicaid drug spending by $40 billion over ten years.

Alternatives to Traditional Insurance Models

As dissatisfaction with PBM opacity grows, alternative models are emerging. The most notable is the direct-to-consumer pharmacy model, exemplified by the Mark Cuban Cost Plus Drug Company (MCCPDC).

Launched in 2022, MCCPDC offers transparent cost-plus pricing, adding a fixed 15% markup to the wholesale cost. An economic evaluation found that patients could save on 11.8% of generic drug prescriptions with a median savings of $4.96 per prescription when purchasing directly rather than through insurance. However, this benefit was concentrated among uninsured patients. For those with Medicaid or robust commercial coverage, the insurance copay was often already lower than the cash price at MCCPDC.

This highlights a key insight: insurance benefit design works best when the negotiated rates are truly low. When PBM markups inflate those rates, alternatives become viable. The rise of these models puts pressure on traditional insurers to increase transparency.

What Comes Next?

The landscape of insurance benefit design is shifting toward greater transparency. The Department of Labor mandated enhanced transparency in Explanation of Benefits (EOB) statements starting January 1, 2025. Patients will soon see detailed breakdowns of generic drug pricing components, including rebates and spread pricing.

Additionally, the Inflation Reduction Act's drug price negotiation provisions, beginning in 2026 for Part D drugs, will allow Medicare to negotiate prices for high-cost medications. The Congressional Budget Office estimates this will generate $98.5 billion in savings over ten years. While these negotiations primarily target brand-name drugs, they signal a broader regulatory push to control overall pharmaceutical spending.

For consumers, the takeaway is clear. Generic drugs remain the cornerstone of affordable healthcare, saving the system hundreds of billions annually. However, understanding your specific plan's formulary, checking for hidden fees, and knowing your rights regarding step therapy and prior authorization is essential. The system is designed to cut costs, but you have the power to ensure those cuts translate into real savings for your wallet.